trilostane has been researched along with Hyperplasia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hara, Y; Harada, Y; Nezu, Y; Osamura, RY; Tagawa, M; Takekoshi, S; Teramoto, A; Teshima, T; Yogo, T | 1 |
| Baden, MY; Hosokawa, Y; Matsuzawa, Y; Obata, Y; Saisho, K; Tamba, S; Yamada, Y; Yamamoto, K | 1 |
| Greminger, P; Groth, H; Vetter, H; Vetter, W; Winterberg, B | 1 |
3 other study(ies) available for trilostane and Hyperplasia
| Article | Year |
|---|---|
Trilostane-induced inhibition of cortisol secretion results in reduced negative feedback at the hypothalamic-pituitary axis.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Animals; Antineoplastic Agents; Corticotrophs; Dihydrotestosterone; Dogs; Feedback, Physiological; Female; Hydrocortisone; Hyperplasia; Hypothalamus; Magnetic Resonance Imaging; Male; Pituitary Gland; Pro-Opiomelanocortin; Receptors, Corticotropin; RNA, Messenger | 2009 |
Long-term efficacy of trilostane for Cushing's syndrome due to adrenocorticotropin-independent bilateral macronodular adrenocortical hyperplasia.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Cushing Syndrome; Dihydrotestosterone; Humans; Hyperplasia; Male; Middle Aged; Time Factors; Treatment Outcome | 2011 |
Primary aldosteronism: treatment with trilostane.
Topics: 3-Hydroxysteroid Dehydrogenases; Adenoma; Adrenal Gland Neoplasms; Adrenal Glands; Adult; Aged; Blood Pressure; Dihydrotestosterone; Electrolytes; Female; Humans; Hydrocortisone; Hyperaldosteronism; Hyperplasia; Male; Middle Aged; Renin-Angiotensin System | 1985 |